Start of the European FAST III study: Angio-derived assessment of blood flow in diseased coronary arteries
Erlangen, Germany
The first patients were recently enrolled in the FAST III trial at the Erasmus University Medical Center in Rotterdam, The Netherlands. This officially marked the beginning of a multicenter, randomized-controlled, open-label study in which the outcome of therapy for coronary artery disease is being investigated after fractional flow reserve has been determined using different methods
